Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Study Identifier
P12-811
CT.gov Identifier
NCT01386684
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Prostate Cancer
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel * Diagnosed with Prostate Cancer * Prescribed Lupron as part of his treatment by his treating physician
    Exclusion Criteria:
    * Currently participating in another prospective study including controlled clinical trials and observational studies. * Patient cannot or will not sign informed consent * Survival expectancy less than 2-3 years as per the treating physician's judgment * Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of Prostate Cancer * History of alcohol or drug abuse * No longer than 6 months of therapy if currently on luteinizing hormone-releasing hormone (LHRH) treatment

    Protocol Summary

    The purpose of this study is to evaluate the Canadian Real Life Evaluation of the Effectiveness of Lupron in the Management of Prostate Cancer.

    Study Locations

    No locations found.